Greenland Mines Ltd
GRMLNasdaq
$0.21
↑ +20.2%Jul 17 close · end-of-day
Price
1Y↓ -83.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$19.6M
Enterprise Value
$9.6M
P/E
—
P/S
—
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$22.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-43.3%
ROIC
-28.7%
Debt / Equity
—
Net Cash
$10.0M
Return 1Y
-84.6%
Company profile
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
- CEO
- Joseph Sinkule
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- New York
- Website
- klothoneuro.com
Management & directors
- Leblanc JeffChief Financial Officer
- Sinkule JosephChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
GRML Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.15↑ +87.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$657,018.00 | -$631,322.00 | -$5.5M | -$7.1M |
| Net income | $1.2M | -$707,458.00 | -$6.2M | -$10.6M |
| Diluted EPS | — | -$0.05 | -$0.32 | -$0.22 |
| Operating cash flow | -$493,043.00 | -$446,916.00 | -$2.9M | -$5.9M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$395,607.00 | -$2.9M | -$1.6M | -$1.6M | -$1.9M | -$1.9M | -$1.8M | -$9.5M |
| Net income | -$451,639.00 | -$3.0M | -$2.1M | -$2.1M | -$4.1M | -$2.9M | -$1.4M | -$13.9M |
| Diluted EPS | -$0.03 | -$0.18 | -$0.07 | -$0.08 | -$0.12 | -$0.05 | $0.03 | -$0.15 |
| Operating cash flow | -$907,423.00 | -$1.1M | -$944,154.00 | -$1.6M | -$2.0M | -$1.1M | -$1.3M | -$5.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Mar 5, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-20 | McGarity Jon | Buy | 140,000 | $0.18 | $24,822.00 | filing |
| 2026-07-16 | LeBlanc Jeff· Chief Financial Officer | Buy | 1,400,000 | $0.18 | $245,280.00 | filing |
| 2026-06-25 | El-Dada Riad Hussein | Sale | 175,000 | $0.23 | $40,547.50 | filing |
| 2026-03-04 | LeBlanc Jeff· Chief Financial Officer | Award | 2,500,000 | — | — | filing |
| 2026-03-04 | El-Dada Riad Hussein | Award | 350,000 | — | — | filing |
| 2026-03-04 | ZENTMAN SAMUEL M | Award | 350,000 | — | — | filing |
| 2026-03-04 | Hirschman Shalom | Award | 350,000 | — | — | filing |
| 2026-03-04 | McGarity Jon | Award | 350,000 | — | — | filing |
| 2026-03-04 | SINKULE JOSEPH· Chief Executive Officer | Award | 2,500,000 | — | — | filing |
| 2025-09-25 | SINKULE JOSEPH· Chief Executive Officer | J | 400,000 | — | — | filing |
| 2025-08-25 | LeBlanc Jeff· Chief Financial Officer | Award | 200,000 | — | — | filing |
| 2025-08-05 | Hirschman Shalom | Award | 70,149 | — | — | filing |
| 2025-08-05 | SINKULE JOSEPH· Chief Executive Officer | Award | 537,180 | — | — | filing |
| 2025-08-05 | McGarity Jon | Award | 14,641 | — | — | filing |
| 2025-08-05 | ZENTMAN SAMUEL M | Award | 153,494 | — | — | filing |
| 2025-08-05 | LeBlanc Jeff· Chief Financial Officer | Award | 156,199 | — | — | filing |
| 2025-07-22 | SINKULE JOSEPH· Chief Executive Officer | J | 2,000,000 | — | — | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.